ChromSystemS - Clinical Chemistry

C hromSystemS D I A G N O S T I C S B Y H P L C & L C-M S/M S

Vitamin D Analysis ® MassChrom 25-OH-VITAMIN D3 AND D2 IN SERUM/PLASMA Reagent Kit, Calibrators and Quality Controls for Tandem Mass Spectrometry FULLY AUTOMATED SAMPLE PREPARATION > Suitable for all Tandem Mass Spectrometers with sufficient sensitivity

XIC of +MRM (6 pairs): 395.3/269.2 amu

25-OH-Vitamin D2

2.4

> Isotopically labelled internal standard > 3PLUS1® Multilevel Calibrator Set

0.5

1.0

1.5

2.0

2.5

3.0

3.5


4.5

25-OH-Vitamin D3

2.3

> 3-epi-25-OH-Vitamin D3 can be separated

R O F D E T A D VALI S TANDEM M

4.0

Time, min

4.4 0.5

1.0

1.5

2.0

2.5 Time, min

3.0

3.5


4.0

4.5

Internal Standard 2.3

2.5 0.5

1.0

1.5

2.0

2.5 Time, min

3.0

For safe diagnostics worldwide. Chromsystems GmbH, Munich, Germany, Phone: +49 89 18930 -300, Fax: +49 89 18930 -399, www.chromsystems.de

3.5

4.0

4.5

Certified according to DIN EN ISO 9001 DIN EN ISO 13485 ISO 13485 CMDR

New Edition! Abused Drugs III: A Laboratory Pocket Guide John Wilson 2010, 131 pages, softcover ISBN 987-1-59425-104-7 Product # 4622

Price only $20; AACC Member $16 HOW TO ORDER Abused Drugs III: A Laboratory Pocket Guide incorporates an encyclopedic listing of drugs commonly seen in overdose. Information included extends from molecular structures and formulas and other common names to pharmacokinetic and metabolic data. Now grown to 200 substances, the guide represents a readily accessible one-stop source for available elimination and excretion information, extent of absorption, protein binding, and metabolism. Taken together the information represents a valuable tool for identifying and assessing the risk posed by the many medications and illicit substances encountered in the emergency rooms and clinical laboratories.

ONLINE: http://www.aacc.org and click on the AACC Store link

CALL: (800) 892-1400 or (202) 857-0717

FAX: (202) 887-5093

MAIL: AACC Customer Service 1850 K Street NW, Suite 625 Washington, DC 20006

www.aacc.org

Information for Authors Clinical Chemistry is published by the American Association for Clinical Chemistry (AACC). The journal welcomes contributions of original information, experimental or theoretical, that advance the science of clinical chemistry. Submissions should adhere to the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” (http://www.icmje.org/). Manuscript Review. Manuscripts are evaluated by anonymous peer reviewers. Authors are usually notified of the disposition of a manuscript within three to four weeks of its receipt. Equal consideration is given to manuscripts in English from any country, whether or not the author is a member of the AACC. Copyright. Manuscripts are considered with the understanding that each author has participated in the work and assumes responsibility for the content; that the authors have disclosed any potential conflicts of interest; that the same information has not been and will not be submitted for concurrent review, nor published elsewhere (other than as an abstract, preliminary report, or poster cited in the manuscript); that unique materials necessary to reproduce the results are available to readers; and that if the manuscript is accepted, copyright will be transferred to the publisher. To convey these assurances, all authors must sign the copyright form provided at acceptance. Unpublished Work. When citing unpublished work or opinions of others, provide a permission letter from them. Manuscript Preparation. Text: Most common wordprocessing software formats are accepted; Microsoft Word is preferred. Use 12-point font, 1-inch margins, and double spacing throughout. Do not use headers or footers, but do number the pages, starting with the title page as page 1. For guidance on manuscript preparation and style, consult our Information for Authors at http:// www.clinchem.org/info_ar/info_authors.shtml. Images: The acceptable image file formats for print publication are TIFF (tagged image file format) and EPS (encapsulated postscript) both at 600 dpi resolution. The figures must be submitted as independent files, not embedded within a word processing document. Microsoft PowerPoint (PPT) files are also acceptable, but each file must have embedded fonts and only one image per slide, one slide per file. Verify that symbols and lettering will be legible when reduced to publication size. Figures should be redesigned or recreated if they do not appear sharp and clear on paper. Authors are advised to use our online Digital Expert evaluation tool to test print figures before submitting them. The author will be required to bear the full cost of the preparation and publication of color illustrations, invited contributions excepted. The charge for the first color figure is $1500. Subsequent color figures or parts of figures are $500 each. Tables: Tables should be created in a common word-processing format. Spreadsheet-generated or embedded image tables should be recreated in the word-processing document and included with the text of the manuscript. Submission and Tracking of Manuscripts. Submit and track status of manuscripts at http://submit.clinchem.org. The complete Information for Authors is available at http:// www.clinchem.org/info_ar/info_authors.shtml. Clinical Chemistry (ISSN 0009-9147) is published monthly by the American Association for Clinical Chemistry, 1850 K Street, NW, Suite 625, Washington, DC 20006. © 2011 The American Association for Clinical Chemistry

AACC Officers Ann M. Gronowski, President Greg Miller, President-Elect Catherine A. Hammett-Stabler, Past President Elizabeth L. Frank, Secretary D. Robert Dufour, Treasurer

6A

Editorial Office Address. For additional information about manuscript submission and reviewing, contact the editorial office. Telephone 202.420.7678; fax 202.833.4576; e-mail clinchemed @clinchem.aacc.org. Address for regular mail or courier: Clinical Chemistry, 1850 K Street, NW, Suite 625, Washington, DC 20006. Subscriptions: Contact the AACC Subscriptions Department at 1850 K Street, NW, Suite 625, Washington, DC 20006. Telephone 800.892.1400 or 202.857.0717; fax 202.887.5093; or Web sites http:// www.clinchem.org or http://www.aacc.org. Annual 2011 rates: Print and online institutional subscription USA $1,158, elsewhere $1,337. Individual subscription USA $350, elsewhere $542. Airmail delivery outside USA is an additional $290. Online only (no print) institutional subscription $776; individual subscription $235. Individual subscriptions are for personal use and not to be used in a library. Reprints: Reprint order forms are mailed to authors with their page proofs. Reprints can also be ordered at any time by contacting the Cadmus Reprint Department. Telephone 1.866.487.5625 or 410.943.3728; fax 410.820.9765. Minimum reprint order is 100 copies. Back Issues: Selected complete back volumes and single copies of current and back issues are available from AACC. Contact the Subscription Department for pricing. Missing Copies: Claims will not be allowed (a) unless we are notified within 3 months after the issue date for domestic and Canadian subscribers, or 6 months after the issue date for foreign subscribers; (b) if notice of a recent change of address has not been received; or (c) if the reason for claim is ‘missing from files’. For claims to be processed, the subscriber’s number and exact name and address as they appear on the mailing label must be included in correspondence. Abstracting and Indexing Services: Clinical Chemistry is covered by Abstracts Express, Analytical Abstracts, Biological Abstracts, BIOSIS, Chemical Abstracts Service, Current Awareness in Biological Sciences, Current Clinical Cancer, Current Contents/Life Sciences, Excerpta Medica/EMBASE, Index Medicus, MEDLINE, Reference Update, Research Alert, Science Citation Index, Sociedad Iberoamericana de Informacioń Cientı´fica (SIIC) Data Bases, and SciSearch. Disclaimers: Manuscripts published in Clinical Chemistry reflect the individual views of their authors and, in the absence of a statement to the contrary, not the views of the institutions with which the authors are affiliated. The contents of advertisements or articles are not to be construed as official statements, evaluations, or endorsements by the Editor or the American Association for Clinical Chemistry. Advertising Inquiries: Contact Scherago International, Inc., 525 Washington Blvd., Suite 3310, Jersey City, NJ 07310. Telephone 201.653.4777; fax 201.653.5205; e-mail [email protected]; Internet http://www.scherago.com. Copyright © 2011 The American Association for Clinical Chemistry. All rights reserved. Printed in the United States of America. Photocopying beyond that permitted by Sections 107 or 108 of the US Copyright Law is authorized by the American Association for Clinical Chemistry, for internal or personal use, provided that (a) the fee is paid directly to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923; or (b) a photocopy license has been granted by the CCC. Fees are subject to change. This consent does not extend to other kinds of copying, such as for general or external distribution, resale, advertising, promotional purposes, or for creating new collective works; for these purposes, contact the Director of Publications, AACC, 1850 K Street, NW, Suite 625, Washington, DC 20006. Telephone 202.857.0717; fax 202.833.4568, e-mail clinchem @aacc.org. Periodicals postage paid at Washington, DC and at additional mailing offices. POSTMASTER: send address changes to Clinical Chemistry, 1850 K Street, NW, Suite 625, Washington, DC 20006.

AACC Board of Directors David E. Bruns David G. Grenache Patricia M. Jones David D. Koch Robert L. Murray Gregory J. Tsongalis

Acetaminophen Acetic Acid Acid phosphatase Albumin Aldolase Alkaline Phosphatase Alpha-1 Acid Glycoprotein Alpha-1 Antitrypsin Alpha-1Acid Glycoprotein ALT Ammonia Amphetamines Amylase Apolipoprotein A-1 Apolipoprotein AII Apolipoprotein B Apolipoprotein CII Apolipoprotein CIII Apolipoprotein E ASO AST (GOT) Barbiturates Benzodiazepines Beta-2 Microglobulin Bile acids Bilirubin Calcium Cannabinoids Carbamazepine Ceruloplasmin

Chloride (Direct) Chloride (Nondirect) Cholesterol Cholinesterase Cholinesterase (Butyryl) CK-MB CK-NAC CO2 Total Cocaine metabolite Complement Component 3 Complement Component 4 Copper Creatinine (Jaffe) Creatinine Enzymatic CRP CRP Full Range (0.3-160mg/l) CRP High Sensitivity Cystatin C Digoxin Direct Bilirubin Direct HDL Cholesterol Direct LDL Cholesterol Ecstasy EDDP Ethanol Ferritin Fructosamine G6P-DH Gamma-GT Gentamicin

GLDH Glucose Glucose/Fructose Glutamine Glutathione Reductase Glycerol Haptoglobin HbA1c/Hb HDL Heart-Type Fatty Acid Binding Protein (H-FABP) IgA IgE IgG IgM Iron Iron (UIBC) Lactate Lactate dehydrogenase Lactic Acid LAP LDH LDL Lipase Lipoprotein (a) Lithium Magnesium Malic Acid Methadone Microalbumin

Myoglobin NEFA Opiates Pancreatic Amylase Phenobarbitol Phenytoin Phosphorus Phosphorus (Inorganic) Potassium Ranbut (Hydroxybutyrate) Ransel (Glutathione peroxidase) Ransod (Superoxide Dismutase) Rheumatoid Factor Salicylate sLDL Sodium Theophyline Therapeutic drugs TIBC Total Antioxidant Status Total Bilirubin Total Protein Transferrin Transthyretin (Prealbumin) Triglycerides TxB Cardio Urea Uric Acid Urinary Protein Valproic Acid Zinc

Optimize your laboratory’s workflow with the RX series of clinical analyzers from Randox. With numerous cost and time saving benefits, in addition to our comprehensive test menu, the RX series will provide ultimate consolidation, flexibility, reliability and quality. Routine Chemistry – Lipids – Specific Proteins – Antioxidants – Therapeutic Drugs Drugs of Abuse – Cardiac – Veterinary – Substrates – Enzymes – Trace Metals – ISE

Visit our website for more information

www.randox.com Randox Laboratories US Limited, 515 Industrial Boulevard, Bardane Industrial Park, Kearneysville, Jefferson County, West Virginia 25430, USA T +1 304 728 2890 Toll Free 8664 Randox F +1 304 728 1890 Toll Free 8664 Randox 1 E [email protected]

Quick Guide to Submission For additional article types and detailed instructions, please see our Information for Authors at http://www.clinchem.org/info_ar/info_authors.shtml. Word Limit

Structured (S) or Unstructured (U) Abstract: Word Limit

Maximum Number of References

Article

3,500

S: 250

40

6

Brief Communication

1,500

S: 250

20

1 each

600

Nonapplicable

6

Nonapplicable

1,500 (500)

Nonapplicable

10

2

Type of Submission*

Citation Classics Clinical Case Study (Case description) w/ 3–5 questions with up to 5 points to remember Clinical Case Study Commentary Editorial Letters to the Editor / Reply

Nonapplicable

Total Number of Tables/Figures

300

Nonapplicable

1,500

Nonapplicable

15

Nonapplicable

Nonapplicable

750

Nonapplicable

5

1 4

Mini-Review

3,500

S: 250

40

Opinion

1,500

Nonapplicable

15

1

Perspective

1,500

Nonapplicable

5

1

Q&A

3,500

Nonapplicable

Review

5,000

S: 250

75

6

75 75

Nonapplicable

5

1

What Is Your Guess? Case description w/ 3 Questions Case discussion

Nonapplicable

Nonapplicable

ⴱThis chart represents common types of submissions to Clinical Chemistry.

Manuscript Formatting

▫ Double-spaced text, 1-inch margin, 12-point font size in Arial, Helvetica, or Times New Roman ▫ Numbered pages with references numbered sequentially in main text ▫ Title page listing title, authors (first name, middle initial, last name), each author’s affiliation during the study, corresponding author’s contact information, running title, keywords, list of any previous presentation of manuscript, and any disclaimers ▫ Reference list formatted according to Information for Authors with Journal abbreviations in the reference list checked against the National Center for Biotechnology Information database (http://www.ncbi.nlm. nih.gov/) ▫ SI units used throughout manuscript according to Information for Authors

Metadata (to be entered online)

▫ A valid and unique e-mail for each author ▫ Authors’ current institution, address, telephone, and fax ▫ Author Disclosure Forms and Contribution Forms to be completed by each author before submission. Copyright Transfer Agreement to be completed by each author after acceptance. ▫ Clinical Chemistry manuscript number of any companion papers (if applicable)

Compliance with Guidelines

▫ A STARD checklist is required for all studies or trials of the diagnostic accuracy or performance of a diagnostic test, a CONSORT diagram is required for all randomized and Phase III trials, a MIAME checklist is required for all studies that present data for microarray experiments. ▫ All studies involving human subjects must indicate that they are in compliance with the Declaration of Helsinki ethical principles for medical research involving human subjects. A statement must be included in the text that Institutional Review Board approval was obtained and written informed consent obtained from study subjects.

Permissions

▫ Written permission from the copyright holder is required to reproduce any copyrighted material

Clinical call for papers Chemistry Impact of Biomarkers, Proteomics and Genomics in Cardiovascular Disease

Clinical Chemistry is pleased to announce a special upcoming theme issue on Cardiovascular Disease edited by Drs. Fred Apple, Stefan Blankenberg and David Morrow titled “Impact of Biomarkers, Proteomics and Genomics in Cardiovascular Disease.” Clinical Chemistry, published by the American Association for Clinical Chemistry, is the most highly cited forum for peer-reviewed, original research in the fields of clinical chemistry and laboratory medicine.

The purpose of this issue is to highlight recent advances in the pathophysiology of cardiovascular disease and the use of current and novel biomarkers—including proteomic and genomic approaches—in the diagnosis, risk assessment, treatment and cost effective management of patients with cardiovascular disease. The science that addresses the advances and controversies that surround novel approaches to personalized medicine will be covered.

Clinical Chemistry invites authors to submit original articles related to cardiovascular disease to be considered for publication in this special issue. Manuscripts are most likely to be favorably received if they address novel technologies to diagnose, treat or prevent cardiovascular disease or its complications.

Potential topics of interest include: s Analytical aspects of high-sensitivity cardiac troponin I and T and their clinical implementation for the s s s s s s

assessment of acute and chronic cardiovascular disease Role of novel biomarkers (single or multiple biomarker strategy) in acute coronary syndromes for assessing risk, selecting and monitoring treatment, and guiding management Novel biomarkers, including proteomic, metabolomic and microRNA-based strategies, for the diagnosis and evaluation of suspected ischemic heart disease Analytical aspects of natriuretic peptides (BNP, NT-proBNP, proBNP, MR-proANP) and their role in diagnosing and managing cardiovascular disease including congestive heart failure Role of genomics for early detection, guiding therapy, and improving patient outcomes in cardiovascular disease Role of biomarkers in predicting cardiovascular risk in the community Role of biomarkers in clinical trials

Be a part of this exciting issue! Submissions must be received through our online submission system at http://submit.clinchem.org no later than July 1, 2011. Your cover letter should express your interest in submitting your paper for consideration for the cardiovascular disease theme issue. Journal guidelines for submission apply as described at the submission website in Information for Authors.

Clinical Case Study *SV.YRI

-RGVIEWIHG]GPSWTSVMRIGSRGIRXVEXMSRWMRXLI EFWIRGISJG]GPSWTSVMRIEHQMRMWXVEXMSR %YXLSVW%RHVIEW4IXIV1EVME7LMTOSZE)FIVLEVH;MIPERH)V[MR7GLPIMGLIV-RKS1PPIV (ITEVXQIRXSJ-RXIVREP1IHMGMRI(MZMWMSRSJ)RHSGVMRSPSK]1IXEFSPMWQ4EXLSFMSGLIQMWXV]ERH'PMRMGEP'LIQMWXV] 9RMZIVWMX]SJ8FMRKIRQIQFIVSJXLI+IVQER'IRXIVJSV(MEFIXIW6IWIEVGL (>( 8FMRKIR+IVQER] 'IRXVEP-RWXMXYXIJSV'PMRMGEP'LIQMWXV]ERH0EFSVEXSV]1IHMGMRI/PMRMOYQ7XYXXKEVX7XYXXKEVX+IVQER] (ITEVXQIRXSJ+IRIVEP4EIHMEXVMGW,EIQEXSPSK]3RGSPSK]9RMZIVWMX]'LMPHVIR´W,SWTMXEP8FMRKIR+IVQER]

-QQIHMEXIEGGIWWEZEMPEFPISR 1E]EXLV+18 [[[GPMRGLIQSVK 7MKR9TXS6IGIMZI'PMRMGEP'EWIW*VII)ZIV]1SRXLEXGPMRGLIQEEGGSVK

''7MWWYTTSVXIHMRTEVXF]EKVERXJVSQ

In the Centre for Internal Medicine, University Medical Centre Göttingen of the Georg-AugustUniversity Göttingen a

PROFESSORSHIP FOR CLINICAL CHEMISTRY (BesGr. W3) has to be filled at the earliest possible time. The holder of the position should improve the research foci in the UMG by the identification, characterisation and application of biomarkers and should actively work on the establishment of new research joint ventures. It is expected that the candidate develops techniques and utilization in the scope of personalized medicine within preventive or clinical medicine. If the necessary requirements are fulfilled by the candidate, she/he will bear responsibility for routine diagnosis in the field of Clinical Chemistry. For this, she/he is a member in the board of directors of the “UMG Laboratory”, which is a core facility for most diagnostic procedures of the University Medical Centre Göttingen. The candidate should cooperate in the management of the “Proteomics Unit”, as well as in the establishment of a central “UMG Biobank”. The candidate represents the discipline Clinical Chemistry within the modular teaching units of the medical faculty. Required is the licence to practice medicine, as well as his or her habilitation or equivalent scientific achievements which have an essential relevance in the major research areas of the UMG (neuroscience, cardiac insufficiency, or cancer research). The other requirements for professors are found in § 25 of the Niedersächsisches Hochschulgesetz from 25 February 2007, modified by article 1 of this act from 10 June 2010 (Nds. GVBI., p. 242). The Stiftungsuniversität Göttingen has the right of appeal. Particulars will be elucidated if requested The Professor will be funded for the first five years by a charity of the Deutsche Vereinte Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e. V.; DGKL. The University Göttingen is interested in increasing the number of women in the areas where they are underrepresented and encourages qualified women to apply. Women will be preferred in case of equal qualifications. Severely handicapped and equally qualified applicants will be preferred. Please submit your application online within the next three weeks after this announcement appeared: http://www.universitaetsmedizin-goettingen.de/content/berufungen_onlinebewerbung.html Queries can be sent to: [email protected]

Presents a Webinar

PSA: Optimizing Its Use in Prostate Cancer Screening and Risk Assessment Wednesday, June 22, 2011 ~ 2:00-3:30 pm Eastern U.S. Time Using the prostate-specific antigen (PSA) test to screen asymptomatic men for prostate cancer has been a source of controversy in the medical community since the 1990s. Some argue that there is not enough evidence to suggest PSA’s use as a screening tool improves patient survival, but others believe the test has been instrumental in reducing mortality from prostate cancer in the U.S., which decreased from 41,400 deaths in 1996 to 27,350 deaths in 2006. Recent data from two clinical trials – the European Randomized Study of Screening for Prostate Cancer (ERSPC) and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) – are not only reigniting the flames of this long-standing controversy, but are also sparking new discussions about what can be done to improve the clinical specificity of PSA and optimize the prostate cancer screening process. Attend this webinar and know: Current recommendations for prostate cancer screening and risk assessment What laboratorians can learn from the results of the ERSPC and the PLCO regarding the impact of PSA screening and how it can be improved The role PSA isoforms, kallikreins and molecular markers can potentially play in designing an optimal diagnostic procedure for screening asymptomatic men for prostate cancer How risk-prediction models that assess PSA test results plus factors such as age, ethnicity and family history can potentially be used to improve the clinical specificity of PSA screening Barriers faced by laboratorians and medical professionals in their efforts to improve the effectiveness of prostate cancer screening Expert advice for optimizing prostate cancer screening and risk assessment today, and potential goals for the improvement of prostate cancer screening in the future The Experts: Lynn Witherspoon, MD, (Moderator), System Vice President and Chief Medical Information Officer, Ochsner Medical Center, New Orleans, LA Hans Lilja, MD, PhD, Attending Research Clinical Chemist, the Departments of Clinical Laboratories, Surgery (Urology Service), and Medicine (Genitourinary Oncology Service), Memorial Sloan-Kettering Cancer Center, New York, NY Andrew Vickers, PhD, Associate Attending Research Methodologist, Memorial Sloan-Kettering Cancer Center, New York, NY Target Audience: This program is designed for laboratorians, pathologists, laboratory directors, clinicians, diagnostic manufacturers, and anyone involved in screening for prostate cancer and assessing a patient’s potential risk of developing prostate cancer. This program is approved by AACC for 1.5 Category 1 ACCENT credit hours. Find out what data from recent European and U.S. clinical trials indicate for the future of PSA testing. Register today!

TO REGISTER Go to www.aacc.org and under “Events”, select “Conferences and Events” and choose this webinar. Once on the webinar page, click “Register” to register online or print a registration form.

New Edition! Biochemical and Molecular Basis of Pediatric Disease, 4th Edition Edited by Dennis J. Dietzen, Michael J. Bennett, and Edward C. C. Wong 2010, 660 pages, softcover ISBN 978-1-59425-100-9, Product # 6114

Price only $124; AACC Member $99 For many years Biochemical Basis of Pediatric Disease, 3rd Edition, edited by Drs. Soldin, Rifai, and Hicks, has served as the critical standard for pediatric clinical laboratory medicine. This new edition, retitled Biochemical and Molecular Basis of Pediatric Disease, 4th Edition, continues the previous edition’s strong focus on understanding the pathogenesis of pediatric disease, emphasizing not only the important role of the clinical laboratory in defining parameters that change with the disease process, but also the molecular basis of many pediatric diseases. Biochemical and Molecular Basis of Pediatric Disease, 4th Edition, includes new chapters in the areas of neonatology, iron metabolism, coagulation, endocrinology, and allergy. All other chapters have been extensively updated, covering nearly all aspects of pediatric disease and the many advances that have been made in recent years. Fifty-two pediatric academic faculty, all nationally known for their pediatric clinical and laboratory expertise, have contributed to this new edition, designed not only for trainees in pediatrics and laboratory medicine, but also for well-established practitioners who wish to keep up with advances in the field and those who would like to better understand the unique aspects of pediatric disease and the clinical laboratory.

HOW TO ORDER ONLINE: http://www.aacc.org and click on the AACC Store link

CALL: (800) 892-1400 or (202) 857-0717

FAX: (202) 887-5093


www.aacc.org

Presents a Webinar

Current Issues in Multiple Myeloma Testing Wednesday, May 25, 2011 ~ 2:00-3:30 pm Eastern U.S. Time Diagnosis of monoclonal gammopathies, also called plasma cell proliferative disorders, has traditionally relied on serum and urine protein electrophoresis and immunofixation electrophoresis to identify monoclonal immunoglobulins. However, the growing clinical acceptance of quantitative serum free light chain (FLC) assays has minimized diagnostic urine testing for the identification of monoclonal plasma cell disorders such as multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), and primary systemic amyloidosis (AL). Nephelometric immunoassays for FLC have the sensitivity to quantitate the low concentrations of free light chains that are normally present in serum, and they can detect changes in the ratio of kappa and lambda FLC production that are indicative of a clonal proliferation of plasma cells. Serum FLC assays have been shown to have the sensitivity for detecting unbound light chains and in conjunction with serum protein electrophoresis can efficiently identify monoclonal proteins associated with multiple myeloma. This program will review the key issues to consider when selecting test options for multiple myeloma and other monoclonal gammopathies. Attend this webinar and you will understand: The spectrum of plasma cell proliferative diseases including MGUS, AL, and MM The sensitivities of various test panels for identifying monoclonal proteins How to classify low-risk MGUS How quantitative immunoassays for serum FLC are being incorporated into testing for diagnosis, prognosis, and monitoring of multiple myeloma The Experts: David F. Keren, MD, (Moderator), Medical Director, Warde Medical Laboratory, Ann Arbor, MI Jerry A. Katzmann, PhD, Associate Professor of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN Target Audience: This program is designed for medical professionals who want to learn more about assays and approaches for diagnosis, prognosis, and monitoring of monoclonal gammopathies. These include clinical laboratorians, physicians, industry reps, consultants and others in related fields. This program is approved by AACC for 1 Category 1 ACCENT credit hour. Supported by a generous educational grant from The Binding Site

TO REGISTER Go to www.aacc.org and under “Events”, select “Conferences and Events” and choose this webinar. Once on the webinar page, click “Register” to register online or print a registration form.

New Edition! Point-of-Care Testing: Needs, Opportunity, and Innovation, 3rd Edition Edited by Christopher P. Price, Andrew St John, and Larry J. Kricka 2010, 593 pages, softcover ISBN 987-1-59425-103-0 Product # 6117

Price only $124; AACC Member $99 Point-of-care testing (POCT) is now considered a key enabler of reform and quality improvement in healthcare. Written by an international list of authors, this book brings together: including the move to patient-centered care developments in this field environment the improved outcomes that results from POCT technology in the complex environment of healthcare, and the leading role that POCT will play in transforming healthcare delivery. The technological developments described in this book demonstrate how all in vitro tests can potentially be delivered at the point of care in the future. The challenge for developer, manufacturer, purchaser, provider and user is to determine which tests will offer the greatest benefit and technology, experience indicates that the biggest challenge for all stakeholders will be transforming the practice of healthcare in order to generate these benefits. This is a ‘must read’ book for all developers and manufacturers of POCT technology, those who develop healthcare policy, those who purchase or commission healthcare services, and those who will use this innovative technology.

HOW TO ORDER ONLINE: http://www.aacc.org and click on the AACC Store link

CALL: (800) 892-1400 or (202) 857-0717

FAX: (202) 887-5093


www.aacc.org

Department of Health and Human Services National Institutes of Health Clinical Center Staff Clinician/Staff Scientist (Clinical), Clinical Chemistry Service, Department of Laboratory Medicine, NIH Clinical Center The National Institutes of Health (NIH) invites candidates with strong clinical, leadership, managerial and scientific credentials to apply for a Clinical Chemist position in the Clinical Chemistry Service, Department of Laboratory Medicine, NIH Clinical Center, Bethesda, MD. The NIH Clinical Center is the largest hospital in the world totally dedicated to translational clinical research with an extensive portfolio of innovative research protocols. The NIH Clinical Center’s Clinical Chemistry Service provides clinical laboratory support for all adult and pediatric inpatients/outpatients participating in clinical research protocols at the NIH and consists of five sections: General Chemistry, Immunoassay, Urine, Special Chemistry and HPLC/Mass Spectrometry. The Service has a longstanding research program directed at new method development as well as collaborative and translational research that is linked to Institute initiatives. The Department continues to have opportunities for creative translational clinical research with Institute colleagues, offering remarkable opportunities for scientific collaboration. In addition, a post doctoral fellowship in clinical chemistry is offered with past trainees having successfully competed for academic positions. The Clinical Chemistry service currently consists of approximately 40 staff members including two senior doctoral level clinical chemists and one post-doctoral fellow. The candidate should possess an M.D. and have completed formal post-doctoral training in clinical pathology at an ACGME-certified residency training program or equivalent program and hold a current medical license to practice in the United States. Alternatively, the candidate could have a Ph.D. and formal post-doctoral training in clinical chemistry resulting in American Board of Clinical Chemistry certification/eligibility. He/she must also have a minimum of 2 years of experience in clinical chemistry practice, beyond their postdoctoral training, that includes evidence of laboratory management experience and interaction with clinicians regarding effective use and interpretation of clinical tests. In addition, candidates should have a record of innovative research productivity including peer reviewed scientific publications. Salary and appointment mechanism will be commensurate with clinical chemistry and managerial experience as well as scientific accomplishments. Applications must be received by May 31, 2011. Reply with a letter of interest, CV and the names of six references to Dr. David Sacks, Chair, Clinical Chemistry, DLM, NIH Clinical Center, c/o Ms. Kathy Hilburn, CC, NIH, Bldg 10, Room 2C427, 10 Center Dr., MSC 1508, Bethesda, MD 20892 or [email protected] The Department of Health and Human Services and NIH are equal opportunity employers.

Opportunity to join the University of Cape Town

Advertising Representatives To view the full advertisement, application requirements and response details, please visit www.uct.ac.za and click on “Vacancies”.

Scherago International, Inc. Director: HERBERT L. BURKLUND Traffic Manager: QIEN PORTER Advertising Sales Manager: JACK RYAN Marketing Manager: STEVEN HAMBURGER ADVERTISING CORRESPONDENCE: 525 Washington Blvd. Suite 3310 Jersey City, NJ 07310 Tel (201) 653-4777 Fax (201) 653-5705

Department of Clinical Laboratory Sciences

We invite applications from candidates who have a professional and academic standing as measured by the applicant’s record in the spheres of teaching of basic or applied medical science, in research and in clinical laboratory management. Requirements: • eligibility for registration with the Health Professions Council of South Africa as a Chemical Pathologist; OR a basic medical qualification and eligibility for registration with the Health Professions Council of South Africa as a specialist, with a professional and academic emphasis on chemical pathology and/or metabolic medicine • the ability to interact with clinicians • participation and involvement in specialist medical clinics • a strong research record with the ability to attract outside funding • demonstrated good administrative, managerial and leadership skills • a record of involvement in postgraduate and undergraduate teaching • Diagnostic Laboratory experience. The position is on the establishment of the University of Cape Town, under the auspices of, and in terms of the agreements between, the University of Cape Town and the National Health Laboratory Service. Closing Date: 20 May 2011

ADVERTISER

1123R/23626

www.ayandambanga.co.za

Professor/Associate Professor and Head: Division of Chemical Pathology

Ref: SR082/11

www.uct.ac.za UCT is committed to the pursuit of excellence, diversity and redress. Our Employment Equity Policy is available at http://hr.uct.ac.za/policies/ee.php.

PAGE NO.

Chromsystems GmbH

2A

Immundiagnostik AG

Cover 4

Mindray Randox Laboratories Roche Diagnostics GmbH Siemens Healthcare

10A 7A 16A Cover 2

Solutions for In Vitro Diagnostics Manufacturing

One-Stop Shopping for Your IVD Needs Benefit from Roche expertise: Reagents and raw materials utilized

by the market leader, for your portfolio. Roche Custom Biotech provides raw materials for Clinical Chemistry

and Immunology testing, including antibodies, cofactors, enzymes, substrates, and buffers. Easily complete your test panels using our Clinical Chemistry OEM

reagents, controls, and calibrators.

custombiotech.roche.com Your Roche Custom Biotech Customer Service Europe, Middle East, Africa, and Latin America +49 621 759 8580 [email protected] Japan +81 3 5443 5285 [email protected]

United States +1 800 428 5433, ext. 14649 (toll-free) [email protected]

Asia Pacific +65 6371 6638 [email protected]

Canada +1 450 686 7050 [email protected]

Roche Diagnostics GmbH Sandhofer Straße 116 68305 Mannheim, Germany © 2011 Roche Diagnostics. All rights reserved.

A91DX-9158-A1-4A00. Not available for sale in the U.S. ©2011 Siemens Healthcare Diagnostics Inc. ADVIA Centaur and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc.

Visit us at IFCC-WorldLab booth #14-01

Just add vitamin D. The Vitamin D Total assay joins the ADVIA Centaur Immunoassay System’s already extensive menu.

www.siemens.com/vitamindtotal

Testing for vitamin D has always been a complicated process. Now labs can test for total 25(OH) vitamin D (D2 and D3) in 18 minutes or less on the ADVIA Centaur® family of instruments — quickly, accurately, and with full automation. This new assay arrives just in time. Demand for vitamin D testing continues to grow, prompted by emerging research on the importance of vitamin D to wellness.

and patients can benefit from getting their vitamin D testing results faster. And it means labs will be better prepared to meet today’s demands — and tomorrow’s. Learn more about how the new ADVIA Centaur Vitamin D Total assay is a viable solution for your lab by downloading educational white papers at www.siemens.com/vitamindtotal

With the new Siemens equimolar Vitamin D Total assay, testing is within the reach of labs of all sizes. That means physicians

Answers for life.

July 24–28, 2011, Atlanta, Georgia Georgia World Congress Center

Education. Networking. Exposition. More than 20,000 Participants. Nearly 700 Exhibitors.

Attend the premier education and networking event for the clinical lab community • Keep up with the latest trends and advances in the profession • Learn from colleagues and peers from around the world • Stay current on continuing changes in the health care environment • Choose from 5 full days of scientific sessions See new science and technology at the largest Clinical Lab Exposition in the world • Evaluate products of nearly 700 vendors in 1,900 booths • Learn about new technologies in clinical, molecular and genetic diagnostics, automation, informatics, POCT, OEM, biotech, and more • Make informed clinical lab purchase decisions • Earn Continuing Education credit for attending the Clinical Lab Expo

Registration Now Open

www.aacc.org/2011am

Forget HPLC! Vitamin analysis with

ID-Vit®

ID-Vit®-Principle (prepared, diluted) patient sample + medium

j 48 h 37° C (Vit B6 : 30° C)

low vitamin concentration

high vitamin concentration

Simple microtiter plate assays: y Vitamin B1 (Thiamin)

Quantifies bioactivity Clinically more relevant than HPLC!

y Vitamin B2 (Riboflavin) y Niacin (Vitamin B3) y Pantothenic acid (Vit. B5) y Vitamin B6 (Pyridoxine) y Vitamin B12 y Folic acid y Biotin (Vitamin H)

PAPER

TRASH

GLAS

HPLC

Time to dump your HPLC!

Immundiagnostik AG · Stubenwald-Allee 8a · 64625 Bensheim · Germany · Phone: +49 (0) 62 51/70 19 00 Fax: +49 (0) 62 51/84 94 30 · [email protected] · www.Immundiagnostik.com